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Background: Cancer rehabilitation research has accelerated over the last decade. However, closer 2 
examination of the published literature reveals that the majority of this work has focused on 3 
psychological interventions and cognitive and behavioral therapies. Recent initiatives have 4 
aggregated expert consensus around research priorities, highlighting a dearth in research 5 
regarding measurement of and interventions for physical function. Increasingly loud calls for 6 
the need to address the myriad of physical functional impairments cancer survivors develop are 7 
published in the literature. A detailed survey of the landscape of published research has not been 8 
reported.  9 
Purpose: This scoping review systematically identified literature published between 2008 and 10 
2018 related to the screening, assessment and interventions associated with physical function in 11 
cancer survivors.  12 
Data Sources: PubMed and CINAHL searched up to September 2018. 13 
Study Selection: Study selection included manuscripts of all levels of evidence on any disease 14 
stage and population. 11,483 articles were screened for eligibility, 2507 full text articles were 15 
reviewed with 1055 selected for final inclusion and extraction.  16 
Data Extraction: Seven reviewers recorded: type of cancer, disease stage, age of subjects, phase 17 
of treatment, time since diagnosis, application to physical function, study design, impairments 18 
related to physical function, and measurement instruments used.  19 
Limitations: Studies not written in English, study protocols, conference abstracts and 20 
unpublished data were excluded.  21 
4
Conclusions: This review elucidates significant inconsistencies in the literature regarding: 1 
language used to define physical function, measurement tools used to characterize function, 2 
and the use of those tools across the cancer treatment and survivorship trajectory. Findings 3 
suggest physical function in cancer research is predominantly measured using general HRQOL 4 
tools rather than more precise functional assessment tools. The authors encourage 5 
interdisciplinary and clinician-researcher collaborative efforts toward a unified definition and 6 
assessment of physical function. 7 







 More than 15.5 million Americans have a history of cancer and by 2026 the American 2 
Cancer Society estimates that this number will increase to 20.3 million.1 Up to 20% of childhood 3 
cancer survivors and 53% of adult cancer survivors have impaired physical function2-6 that 4 
negatively impacts their ability to work, participate in life roles7-11 and increases their risk of 5 
mortality.12-14 Despite the growing population of survivors and their demonstrably high level of 6 
functional morbidity, interventions to maintain and improve physical function are essentially 7 
absent in oncology care outside of overt disability.15,16 Evidence clearly identifies this as a 8 
significant gap in cancer care and suggests the need for focused efforts to eliminate this 9 
gap.15,17-19  10 
When reviewing the literature on physical function and rehabilitation, it is evident 11 
that a clear, consistent and universal definition is difficult to find. The most common 12 
definition the authors came across that they believe resonates best with rehabilitation is 13 
described by Painter and colleagues.20 Painter and colleagues define physical function as 14 
“the ability to perform the basic actions that are essential for maintaining independence 15 
and carrying out more complex activities”.20 An individual’s level of physical functioning is 16 
an essential building block to perform activities of daily living (ADLs) and instrumental 17 
(IADLs).20 In order to adequately manage physical function through the cancer continuum it is 18 
requisite to measure function at appropriate times during cancer care using tools that 19 
provide insight on meaningful changes related to functional decline. While a myriad of 20 
measurement tools exist, there is little insight on how these tools are being leveraged in 21 
research and practice beyond just characterizing symptom burden in cancer cohorts. 22 
Understanding the current practice of functional measurement in cancer care can provide 23 
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insight on why such substantial gaps exist in promoting adequate interventions to manage 1 
physical function among individuals with cancer.   2 
The purpose of this scoping review was to systematically identify literature published 3 
between 2008 and 2018 related to the screening, assessment and interventions associated 4 
with physical function in cancer survivors. 5 
Methods 6 
This review follows the Transparent Reporting of Systematic Reviews and Meta-Analysis 7 
(PRISMA) extension for Scoping Reviews (PRISMA-ScR) checklist and explanation.21  8 
Data Sources and Searches 9 
A systematic search was conducted based on the PICO format:  10 
 Patient: Any individual (across the lifespan) with a current or previous oncologic 11 
diagnosis,  12 
 Intervention: Any study that used patient-reported or clinical measures of physical 13 
function to screen, assess, or to measure an intervention outcome,  14 
 Comparison: Any study that compared interventions designed to improve physical 15 
function, 16 
 Outcomes: Any study that reported the use of measurement tools to screen, assess, or 17 
measure an intervention outcome.  18 
PubMed and CINAHL Plus were searched with the assistance of a National Institutes of 19 
Health Biomedical Librarian using the time period January 2008 to September 2018. Title, 20 
abstract, keyword and MeSH terms were searched using the criteria are outlined in Appendix A. 21 
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Reference lists of all included studies and related systematic reviews were hand-searched for any 1 
additional, relevant literature. 2 
Study Selection 3 
 Inclusion and exclusion criteria were informed by the authors’ intent to review literature 4 
focused on measurement of physical function. Physical function was defined as the ability to 5 
perform the basic actions that are essential for maintaining independence and carrying out 6 
more complex activities.20 Studies included were published after 2008, on a cancer population, 7 
either current or prior, at any point in the lifespan, and included screening, assessment, and/or 8 
intervention related to physical function. All published literature that met these criteria were 9 
reviewed regardless of study design. Because this was a scoping review, which is designed 10 
to provide an overview of the existing evidence base regardless of quality, a formal 11 
assessment regarding levels of evidence was not performed.22 The overarching question the 12 
authors considered for inclusion was the following: “Does the article provide insight on 13 
measurement tools used for screening, assessment and/or intervention related to physical 14 
function in individuals with cancer?” Articles were excluded if they were not available in 15 
English, published prior to 2008, included pharmaceutical interventions, included non-cancer 16 
populations, were non-human studies, were published protocols of ongoing trials, or did not 17 
screen, assess and/or intervene for physical function. Studies of cognitive function were 18 
excluded, as were studies of physiological functions or physical activity that had no clear 19 
measures of physical function included in the study. Studies of female sexual function that did 20 
not include a physical component such as pelvic floor muscle re-training, or movement-based 21 
activity were excluded. Finally, articles that used a quality of life measurement tool that did not 22 
directly assess physical function were excluded. This specifically excluded the Functional 23 
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Assessment of Cancer Therapy (FACT) tools as these examine physical well-being and 1 
symptoms, not physical function as defined by Painter.20,23  2 
Data Extraction 3 
 Seven reviewers extracted data from the included studies using an electronic spreadsheet 4 
with predetermined, standardized content fields. Data extracted from each article included:  5 
Domains of Functional Measurement:  6 
 Screening was defined as use of a measurement tool in order to identify a symptom, 7 
impairment, or problem.24  8 
 Assessment was defined as use of measurement tools to provide a more in-depth, 9 
multidimensional and more comprehensive way to identify the extent of an impairment or 10 
functional problem.24  11 
 Intervention was defined as use of a measurement tools to measure change over time as 12 
the outcome of an intervention.  13 
Phase of Treatment: Prehabilitation, active cancer treatment, survivorship post active treatment, 14 
palliative care 15 
Populations: Pediatric <18, Adult 18-65, Geriatric >65 16 
Stage of Disease: 0-III, All Stages, Metastatic 17 
Time Since Diagnosis: <1 year, 1-5 years, >5 years 18 
Type of Study: Case Study, Editorial or Commentary, Narrative Review, Systematic 19 
Review/Meta-Analysis, Observational trials, Controlled trials 20 
Interval of Measurement: Cross-sectional, Pre-test/Post-test, Repeated Intervals 21 
Measurement Tools Used: Comprehensive list of all measurement tools used in the study that 22 
were specific to physical function.  23 
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If there was a discrepancy in the extracted data, the full-text article was re-examined by two 1 
independent reviewers to arrive at a consensus. No formal quality assessment of individual 2 
manuscripts was undertaken following standard practice for scoping reviews.25 3 
Data Synthesis and Analysis 4 
 Descriptive data extracted under the coded categories were analyzed quantitatively 5 
through summary counts in Microsoft Excel and Tableau. Data was aggregated for analysis 6 
based on the study’s primary application of physical function measures: screening, assessment, 7 
or intervention and the results are presented by these three domains. 8 
Results 9 
 The search identified 11,479 articles following the removal of duplicates. After initial 10 
screening of titles and abstracts, 2,507 references underwent full text review, and 1,055 articles 11 
were included (Supplemental Figure 1). Approximately one-third of the articles included patients 12 
with various cancer diagnoses (30.3%), while the rest focused on a single cancer, most 13 
commonly breast (24.8%) and hematological (8.6%). (Table 1)  Of the trials, 86% included 14 
participants who received some combination of antineoplastic therapies (surgery, chemotherapy, 15 
radiation therapy, and/or hormonal treatments). Of the studies that reported disease stage 16 
(n=650), 11.1% focused on metastatic populations. 17 
Phase of Treatment  18 
Most articles (77%) measured physical function following the completion of active 19 
cancer treatment. Only 16% featured the active cancer treatment phase, and 0.3% were palliative 20 
care. Prehabilitation phase, prior to onset of cancer treatments, was highlighted in 2.6% of the 21 
studies including seven in lung cancer and six in colorectal cancer (Table 1). Prehabilitation 22 
studies that screened physical function most commonly used broad oncologic-based performance 23 
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status measures such as Karnofsky Performance Scale (KPS) and the Eastern Cooperative 1 
Oncology Group (ECOG) performance measure. Alternatively, a number of prehabilitation 2 
studies measured changes in cardiorespiratory fitness, and (ADL)/(IADL) with more specific 3 
measures over the duration of a rehabilitative intervention designed to prepare subjects for their 4 
pending antineoplastic therapies. (Supplemental Table 1) 5 
Of 171 studies focused on physical function during active cancer treatments, 13 (7.6%) 6 
targeted geriatric populations, most commonly prostate cancer, and 16 (9.4%) were pediatric 7 
typically hematologic cancers. (Table 1). Few were undertaken during an isolated cancer 8 
therapy; 0.2% radiation, 1% chemotherapy, and 0.6% hormonal therapy. In these instances, 9 
functional endpoints measured the impact of treatment side effects (e.g. neuropathy, fatigue, joint 10 
arthralgias) or of an intervention, targeting side effects of treatment (e.g. exercise for fatigue or 11 
loss of lean mass). 12 
Most (64%) of the 814 studies of survivorship after active cancer treatment were in the 13 
assessment domain, and 64% of those implemented a cross-sectional design to characterize the 14 
functional impact of various cancer treatments and side effects on the individual (Supplemental 15 
Table 1). Studies classified as screening were primarily observational (69%) that used survey 16 
data from a larger ongoing study, obtained retrospective data on physical functional measures, or 17 
surveyed a population to assess physical function.  One hundred and twenty-eight controlled 18 
trials were conducted, post-active cancer treatment, with 75% of those being intervention trials. 19 
Of studies that reported time since diagnosis, (n=610) 45.5% were conducted on populations > 5 20 
years post completion of cancer treatments, 34.5% were within 1-5 years of treatment and 20% 21 
were <1 year from diagnosis. (Supplemental Table 1)  22 
Age Group of Interest  23 
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The most frequently studied age group (80%) was adults over 18 years, while 9.1% of 1 
studies focused on geriatrics (>65 years old), and 6.5% (n=69) on pediatrics (<18 years old) 2 
(Table 1). Of the adult studies, 4.8% (n=40) highlighted childhood cancer survivors. The 3 
geriatric studies were primarily (41%) breast or prostate cancer but 25% included a variety of 4 
cancer types. Studies focused on geriatric and pediatric populations routinely utilized age-5 
specific functional measures. (e.g. Pediatric Quality of Life Inventory (PedsQOL), 6 
Comprehensive Geriatric Assessment) 7 
Domain of Measurement Application and Functional Measurement Tools 8 
Of the included studies, 61.5% assessed physical function, 19.5% screened for 9 
impairment, and 19.0% applied functional tools to measure effectiveness of an intervention. 10 
Figures 1-3 illustrate the most used tools by type of cancer, for each of the three application 11 
domains. The SF-36 was the most frequently used measure for screening (n=39), assessment 12 
(n=186) and intervention (n=57). Across all three domains, the most commonly used measures of 13 
physical function were SF-36 (29%), the European Organization for Research and Treatment of 14 
Cancer Quality of Life Questionnaire-Cancer 30 (EORTC QLQ-30) (21.5%), specific symptom-15 
based modules of the EORTC (10%), the 6-minute walk test (6MWT) (7.4%), and ‘other self-16 
developed tools’ (13%). The latter term describes tools or surveys developed by authors for their 17 
own use.   18 
Impairment Findings 19 
Impairment data were extracted from controlled trials, observational studies, narrative 20 
and systematic reviews. Up to five impairments (if applicable) and all measurement tools, were 21 
extracted for each article. However, due to the magnitude of data extracted in this scoping 22 
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review, we elected to only report on primary and secondary impairments identified and the first 1 
three measurement tools reported in each study (Table 2). (The reader can review online 2 
supplementary tables for the full data set). The most frequently measured physical impairments 3 
were Health-Related Quality of Life (HRQOL), ADL/IADL/Extended IADLs, swallowing and 4 
speech, incontinence, cardiorespiratory fitness, weakness, sexual function, and cancer-treatment 5 
symptoms (pain, fatigue, lymphedema, and neuropathy). 6 
Table 2 provides a detailed breakdown of the top three measurement tools identified in 7 
studies based on type of cancer and the primary and secondary impairments. Although reviewers 8 
extracted up to 5 impairments from each study and characterized all of the measurement tools 9 
used within a study, only the primary and secondary impairments, and top three measurement 10 
tools are presented, with the remainder of the material available in supplemental files on-line.  11 
Table 2 shows the combination of measures by impairments and reveals that specific 12 
impairment-based measurement tools (measures of balance, swallowing, and incontinence) were 13 
frequently combined with more generic tools like SF-36 or EORTC, likely to characterize a 14 
specific impairment in greater detail than these general tools allow.  The on-line supplemental 15 
table characterize the number of different tools used for impairment measurement.  16 
Discussion 17 
To our knowledge, this is the first scoping review on measurement of physical function in 18 
individuals who have or have had cancer.  Results suggest that in cancer research, physical 19 
function is predominantly measured using general HRQOL tools rather than more precise 20 
functional assessment tools.  Further, results point to inconsistencies in language used to describe 21 
physical function, measurement tools used to characterize function, and application of those tools 22 
across the cancer treatment and survivorship trajectory.  No universally accepted operational 23 
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definition of physical function was identified. Each gap revealed by this scoping review is also a 1 
research and practice opportunity with potential to improve the measurement and management of 2 
physical function in interprofessional cancer care. (Table 3) 3 
Opportunity: Assess function prospectively from a pre-treatment baseline 4 
 In the articles reviewed, physical function assessment was overwhelmingly cross-5 
sectional and occurred well into the post-treatment survivorship phase with >45 % of studies 6 
taking place > 5 years post treatment completion.  Post-treatment functional status is important, 7 
but difficult to interpret without a pre-treatment baseline, or a matched cancer- or treatment-free 8 
comparison group. This highlights one of the most significant gaps in current evidence and 9 
practice; prospective assessment of functional changes from a pre-treatment baseline.  10 
Cancer treatment-related functional problems are under-identified and under-treated.26 11 
Less than 2% of individuals who present with clinically-identifiable functional limitations are 12 
referred for rehabilitation services to manage these limitations.16,27 In the absence of 13 
rehabilitation, conditions like cancer-related fatigue, lymphedema, and chemotherapy-induced 14 
peripheral neuropathy (CIPN) may lead to life-long disability.28,29 Many treatment-induced 15 
impairments that contribute to functional decline during cancer treatment are amenable to 16 
rehabilitation. When intervention is implemented early in the oncology care plan, physical 17 
impairments can be effectively managed to prevent or mitigate functional decline.27,30 18 
Theoretical models that promote proactive functional assessment and interventions to maximize 19 
function, leveraging rehabilitation professionals, were common among narrative reviews and 20 
commentary articles in our results,27,31,32 however controlled trials testing such models were rare.   21 
  Cancer rehabilitation prospective surveillance models were first published nearly a 22 
decade ago yet they are not the clinical standard of care, even for cancers (breast, head and neck) 23 
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with well-documented and predictable neuromusculoskeletal impairments.33-36 The clinical goals 1 
of prospective models are to repeatedly screen and educate at routine intervals during cancer 2 
treatment to facilitate early identification and intervention to mitigate or even prevent functional 3 
decline.32,36 Early identification and management of symptoms does more than support survivors; 4 
recent findings suggest that lifespan is extended when supportive care begins at the time of an 5 
advanced cancer diagnosis.37,38   6 
Baseline functional assessment can also assist medical, surgical, and radiation oncology 7 
teams as they prescribe life-extending cancer therapies.  Often, patients are refused optimal 8 
cancer therapeutics based on a provider’s subjective appraisal of their physical performance. 9 
Using specific patient-reported tools and clinical performance tests may support more accurate 10 
classification of physical function enabling greater precision in oncologic treatment planning.39,40 11 
The model for baseline functional assessment also enables prehabilitation interventions for those 12 
individuals who fall in ‘borderline’ categories for physical tolerance to cancer therapies and may 13 
enable them to jump to the ‘fit for treatment’ category.  14 
As a research opportunity, prospective assessment would provide historical comparison 15 
data for the natural history of functional change during cancer treatment, the absence of which 16 
confounds discussions of how to achieve optimal long-term survivorship.41 Data on proactive 17 
functional changes through cancer treatment can support delivery of exercise and rehabilitative 18 
interventions of the most appropriate intensity in the least restrictive environment to promote 19 
function. Evidence is rapidly growing to support the predictive and prognostic value of baseline 20 
physical function on cancer outcomes, ranging from reduced surgical complications to overall 21 
survival.42,43 Experts have identified physical function as an emerging prognostic biomarker in 22 
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cancer.44 Ample opportunity exists to further explore physical function as a prognostic 1 
biomarker, as there is no single ‘gold standard’ physical function metric.  2 
Opportunity: Identify predictive and informative transdisciplinary tools 3 
While patient-reported and performance measures were both identified, our scoping 4 
review results are clear: physical function was more commonly assessed through patient report 5 
than by actual measurement of physical performance, and the resulting characterization of 6 
function was largely based on subscales of larger HRQOL measures. An optimal tool predicts 7 
meaningful outcomes, informs the specific nature of a survivor’s functional decline and detects 8 
meaningful changes that necessitate triage for intervention. This review identified a 9 
preponderance of non-specific tools applied for both screening and assessment of physical 10 
function; we suspect this is a key factor leading to the relative under-reporting and under-11 
treatment of cancer-related functional problems. 12 
Patient-reported measures 13 
The most frequently used scale to measure physical function was the non-specific SF-36, 14 
followed by the cancer-specific EORTC and its site- and symptom-specific derivations.  These 15 
measures primarily capture HRQOL, but the physical function scales offer a limited assessment 16 
of the broad range of extended ADLs.  Furthermore, these tools may not be responsive to 17 
measuring functional change over time.45  18 
Likely because it is newer, the Patient Reported Outcomes Measurement System 19 
(PROMIS) measures were rarely identified among the articles reviewed. PROMIS uses a 20 
computer-adapted technology (CAT) format with follow-up questions offered or withheld based 21 
on the answer to a ‘stem’ and accommodates individual patient responses. PROMIS offers 22 
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greater responsiveness with less burden.46 A set of PROMIS tools are specifically designed and 1 
validated for cancer populations.47  Another CAT functional assessment tool, the Activity 2 
Measure- Post Acute Care (AM-PAC) is being tested in prospective surveillance trials.48,49 These 3 
individualized tools may provide greater specificity in functional assessment in the future.  4 
Performance measures  5 
Performance measures commonly used in oncology care, such as the ECOG or KPS, are 6 
based on provider observation and lack specificity in functional assessment. Although these 7 
scales provide a quantitative score, they are not informed by objective or quantifiable measures 8 
of performance. Recent reviews in geriatric oncology identify shortcomings in these tool’s 9 
ability to accurately identify important and emerging functional changes, challenging their 10 
specificity as compared to a more comprehensive battery of tests.50,51  11 
Clinical performance measures reported in this review ranged from the Timed up and Go. 12 
(TUG) and 6MWT, to more comprehensive assessments like the Short Physical Performance 13 
Battery (SPPB).  Questions exist regarding the responsiveness of some tools like the Timed Up 14 
and Go (TUG) and the AM-PAC, which were validated in disabled populations outside of 15 
oncology.  Their use in oncologic populations, specifically the potential for ceiling effects when 16 
applied to higher functioning cohorts, is concerning considering the wide variability in 17 
impairment severity that an individual can experience through cancer care.52,53 Many individuals 18 
express self-reported concerns about physical function below their personal baseline, or ‘normal’ 19 
even when their clinical measures improve.53  Reconciling discordant patient-reported measures 20 
and clinical performance measures is a documented challenged.52 21 
Identifying an optimal interdisciplinary tool valid across diverse cancer populations will 22 
prove challenging, especially one that can meet a range of needs across the lifespan. 23 
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Increasingly, validated scales that serve multiple needs in similar populations are often batteries 1 
of tests.54 The geriatric assessment (GA) for cancer survivors is now well-validated battery of 2 
tests and includes a physical performance test (TUG) to supplement patient-report, but as 3 
intended, its validation has been limited to older adults.55,56  Moreover, ADLs and IADLs are 4 
increasingly supported in the literature as predictors of meaningful cancer outcomes specifically 5 
in breast and prostate cancers.57-59 Performance assessment batteries60 fit well within the 6 
expertise of rehabilitation providers, yet our scoping review suggests that IADLs are currently 7 
captured primarily by patient-report, perhaps for feasibility.  8 
Interestingly, recent evidence suggests that gait speed, as a single performance-based 9 
measure of function mobility, is almost as useful as larger batteries like the comprehensive GA 10 
yet is less burdensome and more clinically feasible.61 As a single performance measure valid for 11 
both risk stratification and outcomes assessment, gait speed is one of the physical function tools 12 
validated in oncologic populations53,62 and correlates well with other performance measures 13 
(6MWT, TUG).63   14 
Identifying a single tool capable of capturing all domains of physical function across the 15 
cancer experience (pre-morbid status, cancer site, cancer stage, and the highly individualized 16 
response to treatments), and applicable to all disciplines within cancer rehabilitation, will be no 17 
small task. Emphasis should initially be placed on studying the construct of repeated measures 18 
and these tools’ responsiveness to functional change. Future research endeavors can then explore 19 
effective combinations of measures based on an individual presentation. This patient-specific 20 
approach is being championed by policy makers in oncology care delivery.64  21 
Opportunity: Selective assessment of single antineoplastic modalities or regimens 22 
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In over 80% of articles reviewed, patients had received multiple cancer treatment 1 
modalities (e.g. surgery, radiation and chemotherapy). This is likely due to the propensity of 2 
cross-sectional assessments conducted long after treatment ended. While these studies provide 3 
insight on the incidence of late effects, they fail to characterize mechanisms for functional 4 
decline based on single treatment modalities. More selective prospective observation, with pre-5 
treatment baseline, would inform the critical knowledge gap of mechanisms behind physical 6 
function declines, by specific cancer population and treatment regimen. For example, CIPN is 7 
known to negatively impact ADL’s and functional mobility due to sensory, proprioceptive, and 8 
motor deficits. Functional measures taken before and during the delivery of neurotoxic 9 
chemotherapy agents may facilitate triage for rehabilitative interventions that can mitigate 10 
functional decline.65 Some specificity of functional measures to guide intervention was identified 11 
around the perioperative time period, primarily in breast cancer and targeting restoration of upper 12 
extremity mobility. The premise that surgery incites functional deficits which require 13 
rehabilitative interventions is well regarded.66-68 There is merit to carrying this rationale over to 14 
chemotherapy, radiotherapy, and hormonal therapy as the morbidity burden is equally, if not 15 
more, important in context to the treatment rendered.  16 
Opportunity: Align semantics for concise and precise functional assessment. 17 
Inconsistencies in language and terminology are notable across the studies in this review. 18 
Perhaps this relates to the lack of a universally accepted definition of physical function. The 19 
semantic variations present a conflict when attempting to look across studies and draw 20 
conclusions on optimal approaches to measure and manage physical function.  21 
Physiologic Function vs Body Structure and Function  22 
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We identified significant variance in the clinical measures used and their extrapolations 1 
as a reflection of functional status.  One prominent conflict was physiological functions (e.g. 2 
cardiac ejection fraction, VO2 max, pulmonary expiratory volume) and measures of body 3 
structures and functions (e.g. joint range of motion, muscle power, muscle strength) assessed as 4 
proxies for overall physical functioning. While measures of physiologic function, or of body 5 
structures and functions, provide insight on the components of body systems, they fail to assess 6 
how the individual performs activities and participates in daily life.   7 
Physical Activity vs Physical Function 8 
Some articles purporting to measure physical function actually assessed levels of physical 9 
activity.  To some extent, whether an individual chooses to be active and participate may speak 10 
to their ability to be active and participate. While physical activity prominently features in 11 
observational studies12,69 and changes in physical activity levels correlate to cancer disease end 12 
points, more detailed assessment of how physical function impacts physical activity levels 13 
should be explored as these are two different constructs. Promoting physical activity is a 14 
mainstay of cancer control science, however without perspective on the physical function of 15 
cancer survivors there may be a critical piece missing in the rationale for population approaches 16 
to encouraging physical activity. Physical impairment introduces barriers to achieving optimal 17 
levels of physical activity. Clearly delineating between these constructs yet elucidating on their 18 
dependent relationship is a need. 19 
Body Structure and Function vs. Activities and Participation 20 
While there is an intimate relationship between body structures and functions, and 21 
activities and participation, measures of function in life roles is the most relevant measure of 22 
ability or disability. Individuals may be severely incapacited in body structure and functions (e.g. 23 
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an individual with multiple limb loss), but still able to function in life roles at a high level with 1 
supportive services and devices. Therefore, gross measures of impairment such as joint ROM, 2 
oxygen consumption, and limb volume may minimally reflect an individual’s ability to 3 
participate in life roles. For example, an individual with severe lymphedema may still carry out 4 
self-care strategies independently with modifications. While impairment severity is highly 5 
relevant to a plan of care that improves activities and participation, solely assessing the severity 6 
of one or more impairment in an inadequate measure of function.   7 
Future Recommendations 8 
 Achieving an interval prospective surveillance approach that seeks to optimize physical 9 
function in oncology will require: 10 
1. Reliable, predictive, and responsive measures of physical function. A variety of patient-11 
reported and clinical measures are reported in the literature that examine function, 12 
however many of these lack reported psychometric properties specific to the cancer 13 
population.70-72 Additionally, little is known regarding what objective measures of function 14 
may predict changes in specific symptoms related to cancer. Future studies should 15 
incorporate both patient-reported outcomes as well as objective measures that have sound 16 
psychometrics in the cancer population in order to identify functional deficits that are of 17 
primary concern to individuals with cancer and may result in symptom interference with 18 
functional activities. 19 
2. A framework for proactive, repeated functional measurement through the duration of 20 
cancer treatments to periodically re-assess risk for, or presence of, clinically meaningful changes 21 
in function.  Achieving this aim will require a clear definition of physical function, a rigorous 22 
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and reproducible assessment protocol, and a pathway to clinical implementation that allows for 1 
flexibility in the framework based on the individual, their cancer type and anticipated treatments;  2 
3. Clinical pathways to facilitate triage into rehabilitation systems, promoting proactive 3 
interventions to optimize function throughout the cancer trajectory. This approach not only 4 
positively impacts an individual’s function during cancer treatment but promotes optimal long-5 
term function in this population.41   6 
Limitations of this Scoping Review 7 
We recognize many limitations inherent to this scoping review.  Most importantly, we 8 
urge readers to interpret the findings with attention to the methods used in this literature search 9 
and data extraction.  After careful discussion, the extraction team applied Painter’s published 10 
definition of physical function20, but individual interpretation occurs even within a seemingly 11 
clear definition.  Article selection, initially by review of abstracts and then full text, required 12 
concordance from two reviewers, but there was some opportunity for inter-rater deviation on key 13 
variables during the extraction process.   14 
The operational definitions used in this scoping review are more specific to physical 15 
function than prevailing practice in oncology. While this was intentional to elucidate the gaps in 16 
physical function measures, common practice in clinical trials actually supports the use of non-17 
specific HRQOL tools in clinical trials. 18 
The sheer volume of articles included in this scoping review presented another limitation.  19 
Processing over 7,000 initial hits required significant time from the authorship team, making it 20 
impossible to include newly released articles, yet we recognize that publications on this topic are 21 
growing exponentially.  New publications may counter some of our conclusions by the time of 22 
 
  22
publication. Additionally, while the results are intended for application to the diverse disciplines 1 
of cancer rehabilitation, all authors are physical therapists.  2 
Lastly, we did not assess the feasibility of functional measurement nor reports of the rates 3 
of complete or missing functional data in trials. Time burden is a recognized issue for patients 4 
being asked to complete these tests and assessments. As well, providers experience a time burden 5 
in administering, interpreting, and determining a plan of care based on these tests. Closer 6 
examination of feasibility and models for implementation of a functional framework are needed.  7 
Conclusion 8 
In summary, this scoping review, the first of its nature, adds to the literature on physical 9 
function over the cancer trajectory and across the lifespan.  Functional decline is prevalent in 10 
individuals diagnosed with cancer, both during and after cancer treatments. Functional morbidity 11 
may drive the psychological and emotional issues faced by persons with cancer.  Functional loss 12 
too often goes undetected until severe. Results of this scoping review suggest that one 13 
contributor is a lack of consensus about a single physical function definition, and best measures 14 
of physical function.  While it is clear that both the ECOG and KPS lack the specificity to 15 
measure discrete limitations in physical function, and fall short of prompting triggers for triage to 16 
rehabilitation, we are unable to promote a single tool or assessment battery as a physical function 17 
‘gold standard’ based on results of this review. Research opportunities are vast.   18 
The authorship team encourages interdisciplinary and clinician-researcher collaborative 19 
efforts toward a unified definition and assessment of physical function, one appropriate for both 20 
cancer rehabilitation research and practice. Such efforts should consider current needs for 21 
evidence behind (1) baseline assessment for optimal risk-stratification to inform triage for 22 
prehabilitation, but also immediate cancer treatment prescription, (2) prospective surveillance to 23 
 
  23
capture earliest decline, and (3) outcomes to measure effectiveness of cancer rehabilitation 1 
interventions and preventions.  We encourage the use of measurement tools specific to activity 2 
and participation, and the broad assessment of physical function, beyond physiological tests and 3 
measures that may or may not correlate with overall function. It is likely that no single, static 4 
battery will meet all screening, assessment, and intervention needs in the diverse field of cancer 5 
rehabilitation, across the lifespan, and along the cancer trajectory from diagnosis to late 6 
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Table 1. Descriptive Data  1 
CANCER TYPE  n % 
Bladder 5 0.5 
Breast 262 24.8 
Brain 38 3.6 
Colon 54 5.2 
Gynecological 58 5.5 
Head and Neck 66 6.3 
Hematological 91 8.6 
Lung 25 2.4 
Sarcoma 29 2.8 
Other GI* 21 2.0 
Prostate 64 6.1 
Various** 320 30.3 
Melanoma 7 0.7 
Testicular 5 0.5 
Other cancers 11 1.0 
***Adult Survivors 
of Childhood Cancer 40 4.8 
Disease Stage n % 
0-III 467 44.4% 
All Stages 109 10.3% 
Not Reported 406 38.4% 
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Metastatic(IV+) 73 6.9% 
Phase of Treatment n  % 
Prehabilitation 28 2.6 
Active cancer 
treatment 171 16.2 
Survivorship post-
active cancer 
treatment 814 77.1 
Palliative Treatment 4 0.4 
Population  n % 
Adult >18 842 79.8 
Pediatric <18 69 6.5 
Geriatric >65 97 9.2 
Not reported 46 4.4 
Domain n % 
Screening 206 19.5 
Assessment 648 61.4 
Intervention 200 18.9 
Study Type n % 
Case Report 17 1.6 
Editorial 32 3.0 
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Narrative Review 103 9.7 
Controlled Trials 347 32.9 
Systematic Reviews 85 8.1 
Observational 





Table 2. Breakout of measurement tools in the domains of Screening, Assessment, and Intervention 




Tools (> 5 
studies)* 
Tool (n) 
Short Form-36 (SF-36) 59 
 
European Organization for Research & Treatment of 
Cancer Quality of Life Questionnaire-Cancer 30 
(EORTC QLC-C30) 48 
EORTC Modules 30 
Other self-developed tools 43 
Common Terminology Criteria for Adverse Events 
(CTCAE)  23 
Eastern Cooperative Oncology Group (ECOG) 17 
Pain Visual Analog Scale (VAS) 17 
Comprehensive geriatric assessment  15 
Fatigue VAS 15 
Timed Up & Go (TUG) 13 
MD Anderson Dysphagia Inventory (MDADI) 10 
Karnofsky Performance Status (KPS) 9 
Distress Thermometer  9 
EuroQol instrument-5 Dimensional (EQ-5D) 8 
University of Washington-Quality of Life (UW-QOL) 8 
Expanded Prostate Cancer Index Composite (EPIC-
26) 7 
Pediatric Quality of Life Inventory (PedsQL) 7 
Short Form-12 (SF-12) 7 
Six-minute walk test (6MWT) 6 
 
Type of cancer Impairments (Primary and Secondary) Measurement tools 1 Measurement tools 2 Measurement tools 3
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HRQOL ADL/IADL/ Extended 
IADLs 
EORTC QLQ-C30 EORTC Modules MD Anderson Symptom 
Inventory 






Other self-developed tools   






Daily Activities Rating Scale 
(DARS) 
HRQOL   EORTC QLQ-C30 SF-36   
Health Utilities Index SF-36   
Other self-developed 
tools 
EORTC QLQ-C30 SF-36 
SF-36     
ECOG   
World Health 
Organization Quality of 
Life-100 (WHOQOL-100) 
EORTC Modules   
ADL/IADL/ Extended 
IADLs 
EORTC QLQ-C30 EORTC Modules   
Fatigue EORTC QLQ-C30 EORTC Modules Fatigue Visual Analog Scale 
(VAS) 
Other self-developed tools 
Sexual Function General Health 
Questionnaire (GHQ) 
SF-36 Watts Sexual Function 
Questionnaire* 
Lymphedema ADL/IADL/ Extended 
IADLs 
Lymphedema Symptom 
Intensity and Distress 
Survey-Arm (LSIDS-A) 
    
Water displacement Pain VAS Arm symptom VAS* 
HRQOL EORTC QLQ-C30 EORTC Modules Water displacement 
Upper Limb Function Upper Extremity 
Functional Index (UEFI) 
QuickDASH Pain VAS 
Pain AROM Swelling QuickDASH* 
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Neuropathy ADL/IADL/ Extended 
IADLs 
Neurotoxicity score ECOG  SF-36 




Work Ability Index Work Limitations 
Questionnaire* 
Pain ADL/IADL/ Extended 
IADLs 
Brief Pain Inventory 
(BPI) 
WOMAC Index DASH* 
SF-36 Pain VAS   
Cardiorespiratory Fitness 
  
SF-36  TUG 30 Second Sit to Stand 
Sexual Function HRQOL Pelvic Floor Distress 
Inventory 
ECOG   
Colon HRQOL   EORTC QLQ-C30 EORTC Modules   
ECOG   
ADL/IADL/ Extended 
IADLs 
SF-36 ECOG   
Fatigue EORTC QLQ-C30 EORTC Modules   
Neuropathy   EORTC Modules ECOG  Total Neuropathy Score 
Fatigue Other self-developed 
tools 
Fatigue VAS   
HRQOL Common Toxicity 
Criteria for Adverse 
Events v3 
Total Neuropathy Score World Health Organization 
QOL scale* 
Gynecological ADL/IADL/Extended IADLs 
  




Classification of Function 
(WHO ICF) 
Other self-developed tools   
Fatigue HRQOL Fatigue Questionnaire Patient Health 
Questionnaire-9 
EORTC QLQ-C30* 





Fecal Incontinence Severity 
Index 
  
HRQOL Fatigue EORTC QLQ-C30 SF-36   
SF-36     
Pain KPS EORTC QLQ-C30   
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TUG Fullerton Advanced Balance 
(FAB) 
HRQOL Other self-developed 
tools 
ECOG   
Cardiorespiratory Fitness VO2peak Fatigue VAS   
Sexual Function Fatigue EORTC QLQ-C30 CALGB sexual functioning 
scale 
Other self-developed tools 
HRQOL KPS Fatigue Symptom Inventory 
Revised (FSI TDI) 
SF-12* 
Urinary Incontinence Fecal Incontinence ECOG     
Incontinence Severity 
Index questionnaire 
Questionnaire for Urinary 
Incontinence Diagnosis 
(qUID) 
Fecal Incontinence Severity 
Index* 
Head and Neck ADL/IADL/Extended IADLs 
  
EORTC QLQ-C30 EORTC Modules  University of Washington 
Quality of Life Score (UW-
QOL) 
Fatigue Pain Distress Thermometer     
HRQOL   EORTC QLQ-C30     
EORTC Modules   
N-35 
Other self-developed tools 
Other self-developed 
tools 
EORTC Modules EORTC QLQ-C30 
PSS-HN XeQOLs  EQ-5D-3L 
SF-36 EORTC QLQ-C30 EORTC Modules* 
UW-QOL     
ADL/IADL/ Extended 
IADLs 
6MWT 30-sec Chair Stands Push-up Test 
Joint Mobility EORTC QLQ-C30 EORTC Modules   
Speech and swallowing UW-QOL MD Anderson Dysphagia 
Inventory (MDADI) 
  
Pain SF-36     
Joint Mobility Speech and swallowing Penetration and 
Aspiration Scale 
Functional Oral Intake Scale Therabite ROM scale* 
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Speech and swallowing 
  
Brief ICF Core Set for 
HNC 
BCSQ-H&N UW-QOL 
MD Anderson Dysphagia 
Inventory 
    
Fiberoptic Endoscopic 
Evaluation of Swallowing 
(FEES) 
Swallowing performance 
using water swallow test 
UW-QOL   
Other self-developed 
tools 
Vanderbilt Head and Neck 
Symptom Survey version 




  Pain VAS ROM   
Pain Health Utilities Index 
Mark 3 (HUI3) 
Pain VAS   
Balance   Bruininks-Oseresky Test 
of Motor Performance 
(BOT-2) 
Movement assessment 
battery for children version 2 
(MABC-II) 
University of Quebec in 
Chicoutimi-University of 









  6MWT     
HRQOL SF-36 EuroQol EQ-5D   
Fatigue   Fatigue Questionnaire SF-36   
HRQOL Fatigue Questionnaire SF-36 Other self-developed tools 
Pain SF-36 Rotterdam Symptom 
Checklist (RSCL) 
  
HRQOL Fatigue Lee Chronic Graft V 




Other self-developed tools 
Pain SF-36 EuroQol EQ-5D Global rating scale 





Total Neuropathy Score Bruininks-Oseretsky test of 




Fatigue EORTC QLQ-C30 EORTC Modules Other self-developed tools 
Fatigue Cardiorespiratory Fitness Brief Fatigue Inventory 
(BFI) 
Perceived Self-Efficacy for 
Fatigue Self-Management 




HRQOL   EORTC QLQ-C30 EORTC Modules   
ADL/IADL/ Extended 
IADLs 
SF-36 EORTC QLQ-C30 Other self-developed tools 
KPS BPI * 
Cardiorespiratory Fitness SF-36 dyspnea index   
Melanoma ADL/IADL/Extended 
IADLs 
Weakness ECOG     
Other GI ADL/IADL/Extended IADLs 
  
Balducci ADL score ECOG Cumulative Illness Rating 
Scale Geriatrics (CIRS-G) 
Fecal Incontinence Sexual Function City of Hope Quality of 
Life-Colorectal Cancer 
(COHQOL) 
    
Memorial Sloan-
Kettering Cancer Centre 
(MSKCC) Bowel 
Function Instrument 
EORTC QLQ-C30 EORTC Modules 
HRQOL Fatigue EORTC QLQ-C30     





  Other self-developed 
tools 
    
Fatigue Pain None reported     
HRQOL 
  
PedsQL     
Health Utilities Index Mark 3 Child Health Questionnaire* 
SF-36 Child Health Questionnaire 
Parent Form-50 
  
Prostate Fatigue Pain Fatigue Questionnaire Brief Sexual Function 
Inventory 
Short Form-12* (SF-12) 




    
Pain EORTC QLQ-C30 EORTC Modules   
Sexual Function Expanded Prostate 
Cancer Index Composite 
(EPIC-26) 
    
SF-36 UCLA-Prostate Cancer 
Index (UCLA-PCI) 
KPS 
Urinary Incontinence Health Utilities index Patient Oriented Prostate 
Utility Scale 
Prostate Cancer Index 
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SF-36 UCLA-PCI   
Sexual Function Urinary Incontinence EORTC QLQ-C30 EORTC Modules   
EPIC-26     
Other self-developed 
tools 
Attitudes and Practice 
Survey 
  






Salvage Score (TESS) 
PedsQL Other self-developed tools 
Various ADL/IADL/Extended 
IADLs 
  ECOG KPS   
Medical Expenditures 
Panel Survey (MEPS) 
    
Musculoskeletal Tumor 
Society Scale (MSTS) 
    
Other self-developed 
tools 
ECOG   
Sit to stand   
SF-36 Other self-developed tools   
Fatigue EORTC QLQ-C30 EORTC Modules   
SF-36 BFI   
HRQOL Other self-developed 
tools 
Sit to stand Satisfaction with Life Scale 
Pain EQ-5D-5L Other self-developed tools   
SF-36 Pain VAS Other self-developed tools 
Balance ADL/IADL/ Extended 
IADLs 





TUG Gait speed 
Fatigue   BFI EORTC QLQ-C30 Fatigue Severity Scale* 
HRQOL EORTC QLQ-C30 EORTC Modules   
Weakness TUG Peak isometric knee 
extension force 
  
HRQOL   Other self-developed 
tools 
SF-36   
PedsQL Health Utilities Index Mark 3 Child Health Questionnaire* 
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SF-12 Brief Symptom Inventory 18 
(BSI-18) 
Other self-developed tools 
SF-36     
15D (15 dimensions)   
Impact of cancer 
questionnaire 
City of Hope QOL-Cancer 
Survivors 









Fatigue None reported     
SF-36     
EORTC QLQ-C30 Impact of Cancer (IOC) 
Pain PedsQL     
SF-36     
Sexual Function SF-36 Health Utilities Index Mark 3 UCLA-PCI* 
Urinary Incontinence SF-36 SF-12   
Weakness hand grip strength TUG 5 m max walk speed* 
Neuropathy ADL/IADL/ Extended 
IADLs 
Community Health 
Activities Model Program 
For Seniors 








Neurotip Tip Therm Rod* 
Pain ADL/IADL/ Extended 
IADLs 
Pain VAS SF-36 Pain Disability Index* 
Cardiorespiratory 
Fitness 
Fatigue Brief Cancer Impact 
Assessment (BCIA) 
BSI-18 Perceived Stress Scale (PSS) 
Weakness 20 m gait speed 400 m walk Hand grip strength 









Tools (> 5 
studies)* EORTC QLQ-C30 40 
6MWT 33 
Anthropometric Measures 21 
Other self-developed tools 16 
Handgrip strength 14 
TUG 11 
Multidimensional Fatigue Inventory 
(MFI) 9 
Pediatric QOL Inventory (PedsQL) 9 
Range of Motion (ROM) 9 
 
Disabilities of Arm Shoulder & Hand 
(DASH) 9 
VO2 max 8 
Gait speed 8 
BFI 8 
Pain VAS 7 
Chair stand test 7 
Community Healthy Activities Model 
Program for Seniors (CHAMPS) 7 
Fatigue VAS 7 
Pittsburgh Sleep Quality Index 
(PSQI) 7 
Profile of Moods State (POMS) 6 
Godin Leisure-Time Exercise 
Questionnaire (GLTEQ) 6 
SF-12 6 
EORTC Modules 6 
MD Anderson Dysphagia Inventory 5 
Performance Status Scale for Head 
and Neck Cancer (PSS H&N) 5 
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Piper Fatigue Scale 5 
State-Trait Anxiety Index (STAI) 5 
 
Type of cancer Impairments (Primary and Secondary) Measurement tools 1 Measurement tools 2 Measurement tools 3
Brain ADL/IADL/Extended 
IADLs 
Balance Bruininks-Oseretsky Test 
of Motor Proficiency-2 
(BOT-2) 
VO2 peak   
Fatigue 
  






Barthel Index KPS 
Breast ADL/IADL/Extended 
IADLs 
  DASH Other self-developed tool Other self-developed tools 
EORTC QLQ-C30 ROM Psycholodical adjustment 
scale 
Handgrip strength 6MWT Life Satisfaction Inventory 
Other self-developed 
tools 
    
Cardiorespiratory Fitness SF-36 VO2 max   





Center for Epidemiology 
Studies Depression Scale 
(CES-D) 
SF-12 Pain VAS Sit-and-reach 
SF-36 Level of physical activity   
Pain PROMIS     
Weakness DASH 12MWT ROM 
Balance Weakness Charlson Comorbidity 
Index 
Short physical performance 
battery (SPPB) 
5 times chair stand 
Cardiorespiratory 
Fitness 
  Bruce Protocol  Flowmate spriometer Piper Fatigue Inventory 
Global rating scale     






Symptom Distress Scale  CES-D 
Cardiorespiratory Fitness GLTEQ Body Mass Index (BMI)   
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HRQOL Minutes of moderate-
vigorous Physical 
Activity 
    




Weakness 4MWT Chair stand test One-leg stance 
6MWT Fatigue Severity Scale EORTC QLQ-C30 
accelerometer GLTEQ Submaximal treadmill testing 
Fatigue   Multidimensional Fatigue 
Inventory 
PROMIS Fatigue   
SF-36     
ADL/IADL/ Extended 
IADLs 
Cancer Fatigue Scale  PSQI EORTC QLQ-C30 
HRQOL 5 time sit to stand 6MWT Gait speed 




SF-36     
Pain SF-36     
HRQOL   BPI CES-D State-Trait Anxiety Inventory 
EORTC QLQ-C30     
Constant Murley DASH 
International Physical 
activity questionnaire 
EORTC QLQ-C30 BFI 
Memorial Symptom 
Assessment Scale 
SF-36 Sense of Coherence 
Post Traumatic Growth 
Inventory 
Ten Rules for Highly 
Effective Health Behavior 
EORTC QLQ-C30 
SF-12     
SF-36     
Body Image and 









EORTC QLQ-C30     





SF-36 EORTC QLQ-C30 EORTC Modules 
WOMAC strength testing 
Cardiorespiratory Fitness EORTC QLQ-C30 SF-36   




SF-36 Coopersmith Self-Esteem 
Inventory (SEI) 
Fatigue Symptom Inventory 
Lymphedema   Lymphedema symptom 
intensity and distress 





HRQOL SF-36     
Pain Weakness Mini Mental State Exam FIM   
Sexual Function HRQOL Pain VAS Sexual Activity 
Questionnaire 
Female Sexual Function 
Index (FSFI) 
Weakness Balance Biodex System 3 Pro 
Velocity Spectrum 
Evaluation 
Timed backward tandem 
walk 
Other self-developed tools 
Cardiorespiratory Fitness DASH     
Strength 6MWT VO2 max 
VO2 max Timed sit-to-stand test Sit-and-reach 
Colon ADL/IADL/Extended IADLs 
  
6MWT     
Balance Weakness TUG Modified Clinical Test of 
Sensory Interaction on 
Balance (mCTSIB) 





Tecumseh step test     
Fatigue EORTC QLQ-C30 Multidimensional fatigue 
inventory 
National Comprehensive 




    
PA level Fatigue VAS POMS 
HRQOL Senior's fitness test SF-36 CES-D 
Sit to stand     
Weakness SF-36 Fatigue Symptom Inventory   
HRQOL   EORTC QLQ-C30 6MWT VO2 max 
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Fatigue SF-36     
Sexual Function 
  
Index of Sexual 
Satisfaction (sexual 
distress) 
Female Sexual Function 
Index (FSFI) 






6MWT     
HRQOL ADL/IADL/ Extended 
IADLs 
National Health and 
Nutrition Survey  
    
Cardiorespiratory Fitness Brief Symptom 
Inventory-18 
SF-36 Accelerometer 
Neuropathy SF-36     
Lymphedema ADL/IADL/ Extended 
IADLs 
water displacement circumferential 
measurements 
BMI 
Head and Neck ADL/IADL/Extended IADLs 
  
SPADI Neck Dissection Impairment 
Index 
  
Balance ADL/IADL/ Extended 
IADLs 





Hand grip strength 30 second sit to stand 
HRQOL 
  
EORTC QLQ-C30 EORTC Modules   








Performance Status Scale 
for Head and Neck Cancer  
Functional Oral Intake Scale  
ROM SF-36   
Speech and 
swallowing 
  Modified barium swallow 
test 
MD Anderson Dysphagia 
inventory 










HRQOL EORTC QLQ-C30 EORTC Modules Danish Head & neck Cancer 
Group dysphagia score 
Videofluroscopy Mouth Opening ROM Functional oral intake scale 
Weakness 
  






Balance BOT-2 Tandem gait Hopping on one leg 
Weakness 6MWT muscle strength ankle ROM 
Cardiorespiratory 
Fitness 
Weakness PedsQOL general PedsQOL cancer   
HRQOL ADL/IADL/ Extended 
IADLs 
SF-36     
Patient Specific Functional 
Scale (PSFS) 
  
Fatigue Pain VAS KPS EORTC QLQ-C30 
Weakness ADL/IADL/ Extended 
IADLs 
TUG Timed up and down stairs Checklist Individual Strength 
Lung Fatigue HRQOL Fatigue VAS EORTC QLQ-C30 Distress thermometer 
HRQOL   SF-36     
Cardiorespiratory Fitness SF-36 6MWT   
Prostate ADL/IADL/Extended 
IADLs 
Weakness 6MWT 1-RM 30 second sit to stand 
EORTC QLQ-C30 Late life function and 
disability index (LLFDI) 
Schwartz Cancer Fatigue 
Scale 
Body weight Fatigue Anthropometric 
Measures 
Fatigue Severity Scale 6MWT 
Cardiorespiratory 
Fitness 
Fatigue BMI Senior fitness test battery Pedomteter 
HRQOL ADL/IADL/ Extended 
IADLs 
EORTC QLQ-C30 Sit to stand 2MWT 
Expanded Prostate 
Cancer Index Composite 
(EPIC) 
Risk for Distress Scale   
SF-36 Chair rise test 1-RM 
Urinary Incontinence HRQOL University of California-
Los Angeles Prostate 
Cancer Index 
EPIC   
Incontinence VAS SF-3 PCS 
Weakness ADL/IADL/Extended IADLs 1-repetition maximum 
chest press and leg 
press 
Short physical performance 
battery (SPPB) 
SF-36 
Urinary Incontinence Pelvic floor strength 
measures 
    
Sarcoma ADL/IADL/Extended IADLs 
  
Musculoskeletal Tumor 
Society Scale (MSTS) 
    





KPS ECOG Comprehensive geriatric 
assessment 
FIM     
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PedsQL     
SF-36 EORTC QLQ-C30   




Fatigue BOT-2 GLTEQ TUG 




Accelerometer   
Sickness Impact Profile VO2 max Checklist Individual Strength 
(CIS) 
HRQOL SF-36 LLFDI   
Joint Mobility EORTC QLQ-C30 6MWT SF-36 






Balance   Fullerton Advanced 
Balance Scale 
Balance Efficacy Scale Other self-developed tool 
5 time sit to stand Single heel raises  
Weakness Charlson Comorbidity 
Index 
Community health activity 









EORTC QLQ-C30     
ADL/IADL/ Extended 
IADLs 
SF-36 CHAMPS BMI 
Fatigue Duke Activity Status 6MWT   









HRQOL Accelerometer Handgrip strength Sit-up/push-ups 
EORTC QLQ-C30 6MWT SF-36 





SF-36     
Weakness BMI Anthropometric measures SF-12 
Fatigue   Fatigue VAS Ecological momentary 
assessment 
Rhoten Fatigue Scale 
Oncology Nursing 
Society (ONS) Fatigue 
Scale 
    
ADL/IADL/ Extended 
IADLs 
CIS Sickness Impact Profile  Sleep Quality Scale  
Fatigue Symptom 
Inventory 
    
Balance ECOG Tinetti Mobility Test TUG 
Cardiorespiratory Fitness BFI 30-second chair stand Modified Bruce Protocol 
GLTEQ International Physical 
Activity Questionnaire  
7-day Physical Activity recall 
HRQOL Fatigue Assessment 
Questionnaire 
EORTC QLQ-C30 General Self-Efficacy Scale 
EORTC QLQ-C30 12MWT  
SF-36 Other self-developed tools PSQI 
HRQOL   Cancer Rehabilitation 
Evaluation System 
EORTC QLQ-C30 Quality of Life Index for 
Cancer Patients 
EORTC QLQ-C30 EORTC Modules   
PSQI Physical Activity Scale for 
Elders 




Assessment Scale  
6MWT Timed Sit to Stand test 
TUG SF-36   
SF-36     
EORTC QLQ-C30 EORTC Modules 
LLFDI Community Health Activities 
Model Program for Seniors 
questionnaire 
Cardiorespiratory Fitness EORTC QLQ-C30 Aastrand 6-minute Cycle 
Test 
Hand grip strength 
GLTEQ 6MWT SF-36 
SF-36 other self-developed tool   
Fatigue EORTC QLQ-C30 EORTC Modules Piper Fatigue Inventory 
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SF-36     
Joint Mobility ADL/IADL/ Extended 
IADLs 
DASH BPI Pain VAS 
Neuropathy Pain SF-36 MDASI BPI 
Sexual Function 
  
PCI/EPIC     
Weakness Cardiorespiratory Fitness Anthropometric 
Measures 
Handgrip strength 6MWT 
Fatigue SF-36 BIRS VO2 Peak 
    




Tools (> 5 
studies)* 
Tool n
SF-36  186 
EORTC QLQ-C30 139 
Other self-developed tools 77 





Timed Up and Go (TUG) 19 
KPS 18 
Brief Symptom Inventory 16 
Handgrip strength 16 
Pediatric Quality of Life Inventory 
(PedsQL) 13 
Gait speed 12 
Tool n
Pittsburgh Sleep Quality Index 
(PSQI) 
7 
Multidimensional Fatigue Inventory 7 
Quality of Life Cancer Survivors 
(QOL-CS) 
7 
Impact of Cancer (IOC) 7 
European Prospective Investigation 
into Cancer Physical Activity 
Questionnaire (EPIC) 
7 
Fatigue VAS 6 
University of Washington Quality of 
Life questionnaire (UW-QOL) 
6 
Short Physical Performance Battery 
(SPPB) 
6 
Brief Fatigue Inventory 6 






Toronto extremity salvage score 
(TESS) 12 
ECOG 11 
Musculoskeletal Tumor Society 
Scoring System (MSTS) 11 
Expanded Prostate Cancer Index 
Composite (EPIC) 11 
Pain VAS 11 
BMI 10 
sit & reach 10 
Brief Pain Inventory 8 
Cancer Rehabilitation Evaluation 
System (CARES) 
8 
UCLA Prostate Cancer Index (PCI) 8 
EuroQoL EQ-5D-5L 8 
Performance Status Scale for Head 
and Neck (PSS-HN) 
8 




Late Life Function Disability Index 
(LL-FI) 
5 
Lawton–Brody Index of instrumental 
activities of daily living 
5 
Shoulder Pain and Disability Index 5 
CTCAE 5 
1-RM 5 
chair stand test 5 
Charlson Comorbidity Index 5 
Functional Independence Measure 
(FIM) 
5 
Impact of Event Scale (IES) 5 











Impairments (Primary and Secondary) Measurement tools 1 Measurement tools 2 Measurement tools 3 
Bladder HRQOL Urinary Incontinence EORTC QLQ C-30 EORTC Modules Bladder Cancer Index 
Urinary Incontinence Fecal Incontinence Bladder cancer index   




Weakness Pain Leg power on dominant side 
using Nottingham Leg 
Extensor Power Rig® 
 
Bone ADL/IADL/Extended IADLs Musculoskeletal Tumor 




  Bruininks-Osteretsky Test of 




Perceived Impact Problem Profile 
(PIPP) 
Cancer Rehabilitation Evaluation Sy
Short Form 
Health Utilities IndexTM 
Mark2/3 (HUI2/3) 
 
KPS   
Other self-developed tools  
Romberg Test Childhood Orientation and 
Amnesia Test 
  
HRQOL ECOG RUG-ADL (Resource Utilization 
Groups Activities of Daily Living) 
  
HUNT-3 Based Measures BMI   
Other BRIGANCE Diagnostic 
Comprehensive Inventory of 
Basic Skills–Revised 
    
Balance Other Zurich Neuromotor 
Assessment 
Visuomotor integration (VMI)   
Fatigue Neuropathy Other self-developed tools     
HRQOL   Distress thermometer     
EORTC QLQ C-30 EORTC Modules   
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Pediatric Quality of Life 
(PedsQL) 
   
SF-36    
EORTC Modules   
ADL/IADL/Extended 
IADLs 
EORTC QLQ C-30    
European Quality of Life–5 
Dimensions (EQ-5D) 
EORTC-QLQ-30 EORTC Modules 
Minneapolis-Manchester 






Godin Leisure Time Exercise 
Questionnaire (GLTEQ) 
12-lead ECG Expired gas analysis 
VO2 max SF-36 Satisfaction with Life Scale 
Fatigue EORTC QLQ C-30 BN20 KPS 














DASH   
  
Penn Shoulder Score Shoulder Disability Questionnaire-D
SPADI Shoulder Rating Questionnaire 
ECOG Katz Index of ADLs   
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Geriatric Assessment Adult Comorbidity Evaluation 
Index (ACE-27) 
Charlson Comorbidity Index 
Inventory of Functional Status 
for Cancer (IFSA-Ca) 
Multidimensional Scale of 
Perceived Social Support 
(MSPSS) 
  
Medical Research Council 
scale (muscle power) 
Pain VAS Limb girth 
Other self-developed tools    
Personal Role Domain scale Late Life Function and Disability 
Index 
Other self-developed tool 
ROM Strength other self-developed tools 
SF-12 Other self-developed tools   
SF-36   
  
6MWT 12MWT 
Short Physical Performance 
Battery SPPB 
Standing from a chair test Gait speed 
Work Limitation Questionnaire 
(WLQ) 
Return to work VAS   
Fatigue Late-Life Function and 
Disability Instrument 
Satisfaction with Life Scale 
(SWLS) 
  
HRQOL 12MWT   
  
DASH SF-36 1-RM 
EORTC QLQ C-30   
Fordyce Happiness Measure 
(FM) 
Rosenberg Self-Esteem Scale Cohen’s 10-item Perceived Stress S
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Katz’s activities of daily living 
index 
Lawton–Brody Index of 
instrumental activities of daily 
living 
ECOG 
Maximal aerobic fitness 6MWT 12MWT 
Pain VAS Walking diary Western Ontario and McMaster Univ
Osteoarthritis Index (WOMAC) 
QuickDASH   
SF-36 Late Life Function and Disability 
Index 
  
Joint Mobility DASH ROM   
SPADI ROM   
Lymphedema DASH   
Pain Breast Cancer Treatment 
Outcome Scale 
EORTC QLQ-C30   
Weakness TUG 1RM Back scratch test 
Balance 
  
Tinetti-POMA Gait speed TUG 
Cardiorespiratory 
Fitness 




EORTC QLQ C-30   
  
Functional Impairment Test – 
Hand and Neck/Shoulder/ Arm 
(FITHaNSA) 
International Physical Activity 
Questionnaire (IPAQ) 
DASH 
Fatigue ECOG Physical Activity Readiness 
Questionnaire (PAR-Q) 




HRQOL Scottish Physical Activity 
Questionnaire-2 (SPAQ) 
12MWT BMI 
SF-36   
Other SF-36 Personal Habits Questionniare   





Weakness Naughton protocol estimated 
fitness submax treadmill test 
  
Fatigue   SF-36   
ADL/IADL/Extended 
IADLs 
SF-36   
HRQOL Piper Fatigue Scale SF-36 Cancer Inventory of Problem Situati
Other Cancer Survivor Profile   
Pain SF-36 7-Day Physical Activity Recall 
Questionnaire 
  
HRQOL   EORTC QLQ C-30   
EORTC Modules  
SF-36 
PROMIS SF-36 
Questionnaire on Stress in 
Cancer Patients 
EORTC Modules 
SF-36   
Long Term Quality of Life–
Breast Cancer (LTQOL-BC) 
Scale 
    




adjustment illness scale-self 
report) 
SF-36   
SF-8     
SF-12     
SF-36     
Impact of cancer (IOC) scale   
Other self-developed tools   
Pittsburgh Sleep Quality Index   
Subjective Well-being   
ADL/IADL/Extended 
IADLs 
chair stand test     
DASH     
Lymphoedema Functioning Disability and Health Questionnaire 
EORTC QLQ C-30 EORTC Modules CTCAE 
Fatigue VAS SF-12 Social Provisions Scale for Exercise
Katz’s activities of daily living 
index 
Lawton–Brody Index of 
instrumental activities of daily 
living 
EORTC QLQ-C30 
Other self-developed tools     
PHQ-9 EORTC QLQ-C30   
SF-36     
2 min step test 8ft get up & go 
PF-10 Pittsburgh Sleep Quality Index 
VR-12   
WHOQOL-100   
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Women’s Health Initiative BMI 
WHO-QOL     
Fatigue EORTC QLQ C-30 EORTC Modules   
Impact of Event Scale (IES) Fatigue Symptom Inventory (FSI) 
SF-36   
SF-36 Harvard Alumni Health Study 
Physical Activity Questionnaire 
(HPAQ) 
QuickDASH 
Other SF-36 Ladder of Life Perceived Efficacy in Patient-Physic
Interactions 
Pittsburgh Sleep Quality Index 
(PSQI) 
Symptom experience report (SER) 
Pain EORTC QLQ C-30 EORTC Modules   
Other self-developed tools     
Sexual Function National Surgical Adjuvant 
Breast and Bowel Project 
Breast Cancer Prevention Trial 
(BCPT) Hormonal Symptom 
Checklist 
Modifiable Activity Questionnaire Cancer Rehabilitation Evaluation Sy
Weakness EORTC QLQ C-30 EORTC Modules Handgrip strength 
Joint Mobility   DASH Penn Shoulder Scale ROM 
ADL/IADL/Extended 
IADLs 
Other self-developed tools     
QuickDASH     
Lymphedema AROM Pain VAS Circumferential arm measures 
Pain BreastQ DASH Upper Extremity Functional Index (U
DASH ROM Pain VAS 
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Lymphedema   Psychosocial Adjustment to 







DASH     
Kwan's Arm Problem Scale EORTC Module SF-36 
Penn Shoulder Score Lymph ICF Volumeter 
Fatigue ISL staging criteria for 
lymphedema 
    
HRQOL SF-36 Armer self-reported lymphedema 
symptom scale 
  
Pain DASH McGill Pain Questionnaire- Short 
form 
Social Impact of Arm Morbidity (SIA
Questionnaire 
Short Form McGill Pain 
Questionnaire 




Functional reach Sit & reach Berg Balance Test 
Balance Functional reach Sit & reach   
Patient-specific functional scale (PS
Pain Monofilament set     
Pain ADL/IADL/Extended 
IADLs 
Arthritis Self-Efficacy Scale 
(ASE) 
Pain VAS   
Brief Pain Inventory     
KPS Self-Administered Comorbidity 
Questionnaire 
NPRS 
HRQOL Pain VAS SF-36   
Joint Mobility DASH SF-36   
Weakness DASH Norman Lymphedema 
Questionnaire 
Lymphedema Breast Cancer Quest
 
  64
Sexual Function   Menopause Specific Quality of 
Life Questionnaire 
    
ADL/IADL/Extended 
IADLs 
None recommended     
Other Female Sexual Function Index 
(FSFI) 
Other self-developed tools   
Urinary Incontinence SF-36     
Urinary Incontinence Sexual Function PROMIS     
Weakness ADL/IADL/Extended 
IADLs 
6MWT ROM Handgrip strength 
AROM DASH Penn Shoulder Score 
squat test DASH 6MWT 
Cardiorespiratory 
Fitness 
None recommended     
VO2 max Upper extremity strength Sit and reach 
HRQOL Constant-Murly Rowe score DASH 
Joint Mobility Selective Functional 
Movement Assessment 
(SFMA) 
    
Upper Body Strength and 
Endurance (UBSE) 
DASH   
Colon ADL/IADL/Extended 
IADLs 
  European Prospective 
Investigation into Cancer 
Physical Activity Questionnaire 
EORTC QLQ-C30   
Other self-developed tools     
HRQOL EORTC QLQ C-30 SF-36   





6MWT     
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Fatigue Pain EORTC QLQ C-30 Other self-developed tools   
HRQOL   EORTC QLQ C-30 EORTC Modules   
European Prospective 
Investigation into Cancer 
Physical Activity Questionnaire 
EORTC QLQ-C30   
Modified City of Hope Quality 
of LifeOstomy (mCOH-QOL-
O) 
    
SF-36     
ADL/IADL/Extended 
IADLs 
EORTC QLQ C-30     
European Prospective 
Investigation into Cancer (EPIC) 
physical activity questionnaire 
  




Investigation into Cancer 
Physical Activity Questionnaire 
(EPIC) 
EORTC QLQ-C30   
SF-12     
Other self-developed tools   
Short questionnaire to assess 
health-enhancing physical 
activity (SQUASH) 
    
Fatigue EORTC QLQ C-30     
Fatigue Assessment Scale 
(FAS) 
EORTC QLQ-C30 Self-Administered Comorbidity Que
(SCQ) 





Fatigue Assessment Scale (FAS) BMI 
Neuropathy ADL/IADL/Extended 
IADLs 
EORTC QLQ C-30 EORTC Modules   
HRQOL Chemotherapy-Induced 
Peripheral Neuropathy 
Assessment Tool (CIPNAT) 
SF-36   
Pain   SF-12 Brief Pain Inventory (BPI)   
HRQOL EuroQOL Other self-developed tools   
Sexual Function HRQOL EORTC QLQ C-30     
EORTC Modules   
Germ Cell HRQOL Neuropathy EORTC QLQ C-30     
Gynecological ADL/IADL/Extended 
IADLs 
  6MWT     
National Health Interview 
Survey 
    
National Surgery Quality 
Improvement Database 
questionnaire 
    
Other self-developed tools     






Lymphedema SF-12     
Pain Paffenbarger Physical Activity 
Questionnaire 
Brief Pain Inventory (BPI) Fatigue Symptom Inventory (FSI) 
Sexual Function Supportive Care Needs 
Survey– gynecologic version 
(SCNS-gyne) 
Sexual Function–Vaginal 
Changes Questionnaire (SVQ) 
  





modified Balke protocol Vo2 peak   
Other self-developed tools     
HRQOL   EORTC QLQ C-30 EORTC Modules   
Hornheider Questionnaire     
(HFK-B) 
  
SF-36     
ADL/IADL/Extended 
IADLs 
EORTC QLQ C-30 EORTC Modules McGill QOL 
SF-36 
SF-36     
Cardiorespiratory 
Fitness 
EORTC QLQ C-30 KPS Spirometer 
Fatigue SF-36     
EORTC Modules SCQ 
Pain EORTC QLQ C-30     
Sexual Function EORTC QLQ C-30 EORTC Modules SF-36 
Female Sexual Function Index 
(FSFI) 
Menopausal Rating Scale (MRS)   
SF-36     
Quality of Life Adult Cancer 
Survivors (QLACS) 
  
Urinary Incontinence EORTC QLQ C-30     
SF-36 Other self-developed tools   
Lymphedema Other Limb Volume perometry Gynecologic Cancer 
Lymphedema Questionnaire 
  
Pain Sexual Function Other Self-developed tools     
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Sexual Function Other EORTC QLQ C-30 SF-36 Female Sexual Function Inventory (
Urinary Incontinence Fecal Incontinence Sandvik Incontinence Severity 
Index 
Wexner Fecal Incontinence Scale Epidemiology of Prolapse and Incon
Questionnaire 
Urogenital Distress Inventory 
(UDI) 
    
Weakness 
  
Pelvic floor strength     
Head and Neck ADL/IADL/Extended 
IADLs 
  6MWT     
KPS     
Neck Disability Index (NDI) Shoulder Pain and Disability 
Index 
UW-QOL 




Item Bank (CPIB) 
PROMIS Neuro-QoL 
HRQOL   EORTC QLQ C-30 EORTC Modules   
UW-QOL     
Fatigue SF-12     
Fecal Incontinence EORTC QLQ C-30 EORTC Modules   
Joint Mobility UWQOL Performance Status Scale for 
Head and Neck (PSS-HN) 
  
Other- pls comment WHO Quality of Life–Bref 
Scale 
Australian Therapy Outcome 
Measures (AusTOMs) 
General Self-Efficacy Scale (GSES)
Lymphedema HRQOL None recommended     
Speech swallowing 
  
GRBAS rating system 
(severity rating of voice quality 





MD Anderson Dysphagia 
Inventory (MDADI) 
Performance Status Scale-Head 




  6MWT TUG   
Dizziness Handicap Inventory Brief Fatigue Inventory Migraine Disability Assessment Sca
Fundamental Movement Skills 
Test Battery 
    
Knee Society Score (KSS)     
Musculoskeletal Tumor 
Society Rating Scale (MSTS) 
    
Other self-developed tools     
Pediatric Quality of Life 
(PedsQL) 
Child Health Questionnaire Child Health Ratings Inventories 
Pepper Assessment Tool for 
Disability 
Short Physical Performance 
Battery (SPPB) 
Grip strength 
PROMIS     
SF-36 Other self-developed tools   
UQAC-UQAM test battery     
Weakness 6MWT TUG Handgrip strength 
Balance ADL/IADL/Extended 
IADLs 





Weakness Handgrip strength     
Fatigue   SF-36 Fatigue Questionnaire   
ADL/IADL/Extended 
IADLs 
SF-36 EORTC QLQ-C30   
Pain AQoL-6D Other self-developed tools   
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Physical Distress by Symptom 
Distress Scale (SDS) 




HRQOL         
Cancer Rehabilitation and 
Evaluation System (CARES) 
SF-36 Distress thermometer 
EORTC QLQ C-30 
  
  
Family Environment Scale Brief Symptom Inventory Parent Protection Scale 
None recommended     
Pediatric Quality of Life 
(PedsQL) 
    
SF-12 EORTC Modules   
SF-36     
Charlson comorbidity index   
ECOG   
EORTC QLQ-C30   
General Health Questionnaire 
(GHQ-12) 
  
Human Activities Profile (HAP)   
Other self-developed tools   
Other self-developed tools   
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Brief Symptom Inventory CARES EORTC QLQ-C30 
Child Health Questionnaire 
(CHQ-PF50) 
    
EORTC QLQ C-30     
Sickness Impact Profile Other self-developed tools 
SF-6D     
SF-36     
Fatigue EORTC QLQ C-30 Lawton–Brody Index of 
instrumental activities of daily 
living 
2MWT 
Schedule for the Evaluation of 
Individual Quality of Life-Direct 
Weighting (SEIQoL-DW) 
SF-36   
SF-36     
Pain SF-12 EORTC QLQ-C30 EORTC Modules 
Joint Mobility Pain SF-36 Fatigue Symptom Inventory   
Pain ADL/IADL/Extended 
IADLs 
FMA     
HUI Mark 3 (HUI3)     
Weakness Neck Disability Index (NDI) Checklist Individual Strength-20 
(CIS-20) 
Other self-developed tools 
Sexual Function Fatigue Quality of Life Questionnaire 
for survivors (QLQ-S) 
EORTC QLQ-C30 SX scale 
HRQOL BSFI     





Grip strength     
Balance Other self-developed tools     
Lung ADL/IADL/Extended 
IADLs 
  SF-36 Other self-developed tools   
Cardiorespiratory 
Fitness 
  CPET 6MWT Stair Climbing Test (SCT) 
Fatigue 6MWT EORTC-QLQ-C30 EORTC Modules 
Fatigue HRQOL Brief Fatigue Inventory EORTC QLQ-C30   
HRQOL   EORTC QLQ C-30 EORTC Modules   
SF-8 Lung Cancer Symptoms Scale 
(LCSS) 
  
SF-36     
ADL/IADL/Extended 
IADLs 
EORTC QLQ C-30     
SF-36     
Fatigue Brief Fatigue Inventory KPS Godin Leisure-Time Exercise Quest
Other EORTC QLQ C-30 Other self-developed tools   
Pain Edmonton Symptom Scale Other self-developed tools   
Joint Mobility Pain Northwick Park Neck Pain 
Questionnaire (NPNPQ) 





1RM Respiratory pressure meter TUG 
Melanoma HRQOL   SF-36 Impact of cancer (IOC) scale   
ADL/IADL/Extended 
IADLs 
SF-36     
Other self-developed tools   
Fatigue Hornheide Questionnaire 9 
items short form (HQ-S) 
EORTC QLQ-C30 EORTC modules 
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Lymphedema EORTC QLQ C-30 EORTC Modules   
Neuroendocrine HRQOL   SF-36 Impact Event Scale (IES) General Self-Efficacy Scale (GSES)
other GI ADL/IADL/Extended 
IADLs 
  Other self-developed tools     
Fatigue Pain Other self-developed tools     
Fecal Incontinence HRQOL EORTC QLQ C-30     
Sexual Function EORTC QLQ C-30     
HRQOL   EORTC QLQ C-30     
EORTC Modules   
Brief Illness Perception Questionnai
SF-36 KPS   
ADL/IADL/Extended 
IADLs 
Accelerometer 6MWT Timed sit to stand 
ECOG EORTC QLQ-C30 EORTC Modules 
EORTC QLQ C-30 EORTC Modules EQ-5D 
Female Sexual Functioning 
Index (FSFI) 
EORTC QLQ-C30 EORTC Modules 
Fatigue EORTC QLQ C-30     
EORTC Modules   
Fecal Incontinence Modified City of Hope Quality 
of LifeOstomy (mCOH-QOL-
O) 
SF-12 Duke–UNC Functional Social Suppo
Questionnaire (FSSQ) 
Other EORTC QLQ C-30     
Pain EORTC QLQ C-30 EORTC Modules   
Sexual Function 
  





  TUG Repeated chair stands Handgrip strength 
Fatigue PROMIS     
Weakness 400m walk 6MWT TUG 
HRQOL   EORTC Modules EORTC Modules EQ-5D 
UCLA Prostate Cancer Index 
(PCI) 
PCQoL 
EORTC QLQ C-30     
EORTC Modules   
European Prospective 
Investigation into Cancer 
Physical Activity Questionnaire 
Brief Symptom Inventory   
SF-12 Expanded Prostate Cancer Index 
Composite (EPIC) 
Appraisal of Illness Scale (AIS) 
Satisfaction with Life Scale 
SF-36     
ADL/IADL/Extended 
IADLs 
EORTC QLQ C-30 Walking distance Sit and reach 
Godin Leisure-Time Exercise 
Questionnaire 
SF-36 400m walk 
SF-12     
SF-36 UCLA Prostate Cancer Index 
(PCI) 
  
Fatigue European Prospective 
Investigation into Cancer 
Physical Activity Questionnaire 
SF-12 Other self-developed tools 
Pain UCLA Prostate Cancer Index 
(PCI) 
    
Sexual Function Expanded Prostate Cancer 
Index Composite (EPIC) 
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Quality of Life Questionnaire 
for survivors (QLQ-S) 
SF-36 EPIC 
Urinary Incontinence EORTC QLQ C-30 EQ-5D-5L   
Expanded Prostate Cancer 
Index Composite (EPIC) 
Supportive Care Needs Survey 
(SCNS-SF34) 
Modified Self-efficacy Scale 
Patient oriented prostate utility 
score (PORPUS) 
International Prostate Symptom 
Score 
International Index of Erectile Funct
Patient-Oriented Prostate 
Utility Scale (PORPUS) 
5-item International Index of 
Erectile Function (IIEF) 
International Prostate Symptom Sco
SF-12 Expanded Prostate Cancer Index 
Composite (EPIC) 
  
UCLA Prostate Cancer Index 
(PCI) 
Expanded Prostate Cancer Index 
Composite (EPIC) 
  
Other self-developed tools   
Sexual Function Urinary Incontinence Expanded Prostate Cancer 
Index Composite (EPIC) 
    
Urinary Incontinence   UCLA Prostate Cancer Index 
(PCI) 
    
Fecal Incontinence EORTC QLQ C-30 EQ-5D-5L   
UCLA Prostate Cancer Index 
(PCI) 
SF-36   
Weakness ADL/IADL/Extended 
IADLs 
Bench and leg press tests Seniors’ Fitness Test SF-36 
Sarcoma ADL/IADL/Extended 
IADLs 
  Assessment of Motor and 
Process Skills (AMPS) 
    
MSTS     
Musculoskeletal Tumor 
Society Rating Scale (MSTS) 
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Toronto Extremity Salvage 
Scale (TESS) 
    
Reintegration into Normal Living 
Index (RNL) 
  
UCLA sports activity score     
Cardiorespiratory 
Fitness 
6MWT Brief Symptom Inventory Physical Assessment Battery 
HRQOL 6MWT Sit & reach Balance 
Musculoskeletal Tumor 
Society Rating Scale (MSTS) 
Toronto Extremity Salvage Score 
(TESS) 
SF-36 
Other self-developed tools     
Pain Musculoskeletal Tumor 
Society Rating Scale (MSTS) 
    
Other self-developed tools     
Sexual Function Toronto Extremity Salvage 
Scale (TESS) 
    
HRQOL   EORTC QLQ C-30 SF-36 Musculoskeletal Tumor Society Rat
(MSTS) 
Musculoskeletal Tumor 
Society Rating Scale (MSTS) 
Toronto Extremity Salvage Scale 
(TESS) 
SF-36 
Toronto Extremity Salvage 
Scale (TESS) 
    
ADL/IADL/Extended 
IADLs 
SF-36 Toronto Extremity Salvage Scale 
(TESS) 
Timed sit to stand 
Toronto Extremity Salvage 
Scale (TESS) 
EORTC QLQ-C30 SF-36 
SF-36 Brief Symptom Inventory (BSI) 
Testicular HRQOL   Cancer Assessment for Young 
Adults (CAYA) 
    





SF-36     
Fatigue SF-36     
Various ADL/IADL/Extended 
IADLs 
  6MWT     




Adolescent Activity Card Sort 
(AACS) 
  
DASH     
Duke Activity Status Index BMI Physical Performance Test (PPT) 
EORTC QLQ C-30 SF-12 SF-36 
Functional Independence 
Measure (FIM) 
    
Grooved pedboard Other self-developed tools   
Nagi’s Performance 
Limitations Index 
    
National Disability Database 
query 
    
Occupational Self-Assessment 
(Version 2.2) 
    
Other self-developed tools     
Gait speed   
Patient neurotoxicity 
questionnaire 
    
PROMIS Other self-developed tools   
Return to work statistics     
Rosow-Breslau questionnaire     
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SF-36 Brief Symptom Inventory CCSS Neurocognitive scale 
Other self-developed tools   
SF-37 OARS KPS 
Short Physical Performance 
Battery SPPB 
    
Useful Field of View (UFOV®) WAIS Digit Symbol Substitution Timed Instrumental Activities of Dai
Vulnerable Elders Survey 
(VES) 




Work Related Activity 
Limitation Questions 
    
Cardiorespiratory 
Fitness 
EORTC QLQ C-30 Other self-developed tools   
Handgrip strength SF-36   
Other self-developed tools     
SF-36     
Fatigue Geriatric assessment Mini Mental Status Exam 
(MMSE) 
Katz Index of ADLs 
Short questionnaire to assess 
health-enhancing physical 
activity (SQUASH) 
Accelerometer   
HRQOL AM-PAC PROMIS ECOG 
Childhood Cancer Survivor 
Study Questionnaire 
    
DASH     
EORTC QLQ C-30 SF-36   




PROMIS SF-36   
SF-36 Physical performance test (PPT) 6MWT 
Toronto Extremity Salvage Scale 
(TESS) 
Quality of Life for Cancer Survivors 
Other Modified Activity Card Sort 
(ACSm) 
    
Other self-developed tools     
Pain Behavioral Risk Factor 
Surveillance System Survey 
Questionnaire 
Brief Symptom Inventory   
Other self-developed tools     
Supportive Care Needs 
Survey Long Form 
(SCNSLF59) 
    
Sexual Function ICF cancer survivor core set     
Weakness 6MWT    
Short Physical Performance 
Battery (SPPB) 
    
Sit to stand Lateral step up test PedsQL 
TUG     
6MWT Strength 





6MWT  PFTs  SF-36 
HRQOL 6MWT     
VO2 max     
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WHODAS 2.0     
HRQOL EORTC Modules EORTC QLQ-C30 ECOG 
EORTC QLQ C-30 EORTC Modules SF-36 
Modified Tampa Scale for 
Kinesiophobia-Fatigue 
EORTC QLQ-C30   
SF-36 Fatigue Questionnaire (FG) Other self-developed tools 
Pain 6MWT SF-36 Fatigue Symptom Inventory (FSI) 
Memorial Symptom 
Assessment Scale 
    
Sexual Function 2010 LiveStrong Foundation 
Survey 
    
Weakness Stair Climbing Leg Power Test Fatigue VAS   
HRQOL   Cancer Rehabilitation and 
Evaluation System (CARES) 
EORTC QLQ-C30 EORTC Modules 
EORTC Modules  European Prospective 
Investigation into Cancer (EPIC) 
physical activity questionnaire 
 Prostate Cancer Symptom Indices 
EORTC QLQ C-30  EORTC Modules   
Rosenberg Self-Esteem Scale 
(RSES) 
Personal Resource Questionnaire (
SF-12 EORTC Modules 
SF-36   
European Quality of Life–5 
Dimensions (EQ-5D) 





IOC-AYA SF-36 Brief Symptom Inventory (BSI) 
Minneapolis-Manchester 
Quality of Life Survey - 
Adolescent Form 
Pediatric Quality of Life Inventory 
(PedsQL) 
  
Other self-developed tools     
Pediatric Quality of Life 
(PedsQL) 
Godin Leisure-Time Exercise 
Questionnaire (GLTEQ) 
  
Hopkins Symptom Checklist-10 
(HSCL-10) 
  
PROMIS  SF-36   
QOL-CS Quality of Life Adult Cancer 
Survivors (QLACS) 
SF-36 
Quality of Life Questionnaire 
for survivors (QLQ-S) 
Quality of Life Adult Cancer 
Survivors (QLACS) 
SF-36 
SF-12  EQ-5D-5L  EORTC QLQ-C30 
SF-36  7-Day Physical Activity Recall 
Questionnaire (7-DPARQ) 
  
EORTC QLQ-30 EORTC Modules 
EORTC QLQ-C30 Distance walked 
Fatigue VAS 
Impact of cancer (IOC) scale   
Other self-developed tools   
Quality of Life Index (QLI) Assessment of Survivor Concerns (A
SF-12   
ADL/IADL/Extended 
IADLs 
EORTC QLQ C-30  EORTC Modules   
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Multidimensional fatigue inventory 
Fatigue Assessment Scale (FAS) EORTC Modules 
Pediatric camp outcome 
measure (PCOM) 
    
Pediatric Quality of Life 
(PedsQL) 
Multidimensional Fatigue Scale   
PROMIS     
SF-12     
SF-36 Brief Symptom Inventory   
Late Life Function and Disability 
Index 
Community Health Activities Model 
Seniors questionnaire 
Supportive Care Needs 
Survey (SCNS-SF34) 
    
Cardiorespiratory 
Fitness 
EORTC QLQ C-30 Aastrand 6-minute Cycle Test Handgrip strength 
CPET (electrically braked cycle 
ergometer) 
  
PFTs 6MWT   
Fatigue EORTC QLQ C-30     
SF-36 Tampa Scale for Kinesiophobia 
Other self-developed tools SF-8   
Problems and Goals (P&G) 
Assessment 
    
Satisfaction with Life Domains 
Scale-Cancer 
Modified Rotterdam Symptom 
Checklist 
  
SF-36 EORTC QLQ-C30 SF-12 
Multidimensional Fatigue 




HRQOL EORTC QLQ C-30     
SF-36 VR-12   
Other Brief Symptom Inventory SF-36   
SF-36 Brief Symptom Inventory BMI 
Other self-developed tools   
Pain Brief Pain Inventory John Henryism Active Coping 
Scale (JHACS) 
Barriers Questionnaire (BQ-II) 
Urinary Incontinence SF-36 SF-12   
Weakness 6MWT 400m walk Stair climb 
SF-36 Strength   
Joint Mobility Cardiorespiratory 
Fitness 
Schedule for the Evaluation of 
Individual Quality of Life-Direct 
Weighting (SEIQoL-DW) 
    
Lymphedema   Other self-developed tools     
Cardiorespiratory 
Fitness 
Short Physical Performance 
Battery SPPB 
6MWT SF-36 
Neuropathy HRQOL CTCAE-V3 Total Neuropathy Score EORTC QLQ-C30 
Pain MD Anderson Symptom 
Inventory - Traditional Chinese 
Medicine (MDASI-TCM) 
SF-36   
Pain Fatigue Other self-developed tools     
HRQOL EORTC QLQ C-30 KPS   
Sexual Function   5 As—Ask     
HRQOL Sexual Functioning 
Questionnaire (SFQ) 
Women’s Health Questionnaire 
(WHQ) 
Sexual Self-Schema (SSS) for wom
SF-12 Pediatric Quality of Life Inventory 
(PedsQL) 
Multidimensional Fatigue Scale 
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UCLA Prostate Cancer Index 
(PCI) 
UCLA EPIC International Index of Erectile Funct
Pain Pain VAS Quick scale for sexual function   
Urinary Incontinence Fecal Incontinence Other self-developed tools     
Sexual Function Other self-developed tools     
Weakness   Lower-limb muscle strength Lawton–Brody Index of 
instrumental activities of daily 
living 
Brief Fatigue Inventory 
ADL/IADL/Extended 
IADLs 
Sit to stand 1-RM Muscle endurance 
Balance BOT-2 M-ABC balance subtest Berg Balance Test 
 
* Represents studies using >3 measurement tools, this information is available through the supplemental material on-line 




Table 3. Knowledge Gaps Present in Cancer Rehabilitation Research and Clinical Practice 1 
Opportunities  2 





Universal Physical Function 
Definition 
 Identify gold standard 
tools/battery for cancer 
settings: Validate reliable core 
measures with minimal floor 
& ceiling, responsive to a 
range of cancer treatments and 
across the lifespan 
Achieve interprofessional 
collaboration toward unified 
definition of PF, responsive to 




Physical Function assessment  
 
 Expand the evidence-base on 
predictive and prognostic 
value of baseline Physical 
Function for outcomes 
including treatment tolerance 
and overall survival. 
Inform surgical, medical, 
radiation oncology for 
Physical Function 
consideration during 
prescription of cancer 
treatment (modality and/or 
dose). 
Prospective Physical Function 
assessment, start BEFORE 
cancer treatment 
 Establish value & 
effectiveness of cancer rehab 
prospective surveillance 
models  
Quantify natural history of 
Physical Function by cancer 
site and treatment 
Provide pre-emptive education 
for early detection of new 
deficits over the course of 
cancer treatment; Assist 
radiation and medical 
oncologists in titrating 
treatment dose based on 
patient response. 
Prospective assessment 
focused on impact of a single 
agent or specific multi-modal 
regimen 
 Identify mechanisms behind 
functional decline 
Assist medical and radiation 
oncology colleagues in 
titrating dose for individual 
patient response. 
Prehabilitation  Expand the evidence-base on 
prehab approaches as 
improving treatment outcomes 
and survival, with prehab 
models targeting cancer site- 
and treatment-specific factors, 
and designed to inform 
specifics of prescription 
Implement existing evidence 
for prehabilitation by 
promoting these models as 
standard of care. 
PROMIS Physical Function 
Scales for Cancer 
 Establish expanded 
psychometric properties for 
use to screen, assess, and 
capture change with 
intervention in cancer rehab 
Initiate/ expand use of CAT-
based measures to quantify 
severity of deficit and capture 
change to justify care. 
Performance-based 
assessment 
 Enrich study assessments by 
complementing patient-
reported outcomes with actual 
measures of performance, 
known to capture 
Supplement patient-reported 
outcomes with tests less prone 
to intentional censorship of 
deficits (e.g. for fear of 
treatment discontinuation).  
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complementary but distinct 
aspects of the domain. 
Outcomes to Capture Physical 
Function Change in Response 
to Cancer Rehab Interventions  
 Validate best outcomes to 
capture change in PF, and use 
in studies of interventions to 
rehabilitate and prehabilitate 
Physical Function
Measure and report individual 
PF-focused outcomes of 
cancer rehabilitation in 
provision of value-based care. 




Figure 1. Frequency of Screening Measurement Tools by Cancer 2 
Figure 2. Frequency of Assessment Measurement Tools by Cancer 3 

















Appendix A – Search Criteria 1 
PubMED 9369  CINAHL 4437 (after filters Human, English, Last 10 years) 2 
3 
(((Cancer and Survivor or survivorship)) AND (Function or functional or clinical and assessment 4 
or screening or measurement OR outcomes)) AND (activities of daily living OR ambulation OR 5 
amputation OR anemia OR anorexia OR arthralgia OR arthralgias OR balance OR bone density 6 
OR cardiopulmonary fitness OR cardiotoxicity OR clinical OR distress OR dyspnea OR edema 7 
OR oedema OR endurance OR exercise capacity OR fall OR falls OR fatigue OR fatigued OR 8 
fibrosis OR fitness OR flexibility OR frail OR frailty OR function OR functioning OR functional 9 
OR heart failure OR independent activities of daily living OR insomnia OR immobility OR 10 
immune suppression OR impairment OR impairments OR limb salvage OR lymphedema OR 11 
lymphoedema OR mobility OR morbidity OR muscle strength OR neutropenia OR neuropathy 12 
OR neurotoxicity OR ototoxicity OR paresthesia OR performance status OR quality of life OR 13 
pain OR paralysis OR physical performance OR physical strength OR radiculopathy OR range of 14 
motion OR respiratory function OR return to work OR risk reduction OR scar OR seizures OR 15 
self-care OR sensation OR sensory OR shortness of breath OR skin OR sleep OR strength OR 16 
survival OR swelling OR symptom OR symptoms OR thrombocytopenia OR tissue contracture 17 
OR walk OR weakness OR weight OR work OR wounds) 18 
19 
